A Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 2
18+
1 site in PA
What this study is about
This Phase 2 study is focused on people with pancreatic ductal adenocarcinoma. The primary outcome being measured is Objective Response Rate (ORR).
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Objective Response Rate (ORR)
Secondary: Disease Control Rate (DCR) per RECIST v1.1, Duration of Response (DoR) per RECIST v1.1, Incidence of treatment emergent serious adverse events (TESAEs), Incidence of treatment modification due to adverse events, Incidence of treatment-emergent adverse events (TEAEs), Overall Survival (OS), Progression-Free Survival (PFS) per RECIST v1.1, Time to Progression (TTP) per RECIST v1.1